Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Non-Current Deffered Revenue (2021 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 57.35% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 57.35% year-over-year, with the annual reading at $1.5 million for FY2025, 57.35% down from the prior year.
  • Non-Current Deffered Revenue hit $1.5 million in Q4 2025 for Bolt Biotherapeutics, down from $2.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $14.2 million in Q4 2021 to a low of $1.5 million in Q4 2025.
  • Historically, Non-Current Deffered Revenue has averaged $8.2 million across 5 years, with a median of $9.1 million in 2023.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 48.78% in 2022 and later tumbled 62.37% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $14.2 million in 2021, then dropped by 9.05% to $12.9 million in 2022, then dropped by 29.52% to $9.1 million in 2023, then plummeted by 60.25% to $3.6 million in 2024, then plummeted by 57.35% to $1.5 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for BOLT at $1.5 million in Q4 2025, $2.0 million in Q3 2025, and $2.6 million in Q2 2025.